Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies

verfasst von: Xiang Tong, Jiqiao Yang, Yuanling Peng, Jiani Shen, Tianyuan Xiong, Yonggang Zhang, Hong Fan

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The associations between the Arg280His polymorphism in X-ray repair cross-complementing gene 1 (XRCC1 gene) and hematological malignancies have been extensively investigated. However, the results were inconsistent. The objective of the current study was to investigate the associations between the Arg280His polymorphism in XRCC1 gene and the risk of hematological malignancies by meta-analysis. We searched PubMed, Embase, CNKI, Wanfang, and Weipu databases, covering all studies until 07 Aug 2013. Statistical analysis was performed by using the Revman4.2 software and the Stata10.0 software. A total of 2,650 cases and 3,856 controls in 12 case–control studies concerning the Arg280His polymorphism were included. The results suggested that the Arg280His polymorphism might not be associated with risk of hematological malignancies (OR = 1.08, 95%CI = 0.86–1.35, P = 0.50). In the subgroup analyses by cancer types and ethnicity, no significant associations were found among different cancers or different ethnicities. The current meta-analysis indicated that the Arg280His polymorphism in the XRCC1 gene might not be a risk factor for hematological malignancies. In future, more large-scale case–control studies are needed to validate these results.
Literatur
2.
Zurück zum Zitat Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA: J Am Med Assoc. 2011;306(17):1874–83. doi:10.1001/jama.2011.1558.CrossRef Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA: J Am Med Assoc. 2011;306(17):1874–83. doi:10.​1001/​jama.​2011.​1558.CrossRef
3.
Zurück zum Zitat Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. New England J Med. 2013;368(19):1771–80. doi:10.1056/NEJMoa1212772.CrossRef Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. New England J Med. 2013;368(19):1771–80. doi:10.​1056/​NEJMoa1212772.CrossRef
4.
Zurück zum Zitat Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–16. doi:10.1016/S0140-6736(12)60689-8.PubMedCrossRef Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–16. doi:10.​1016/​S0140-6736(12)60689-8.PubMedCrossRef
5.
Zurück zum Zitat Ganster C, Neesen J, Zehetmayer S, Jager U, Esterbauer H, Mannhalter C, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2009;48(9):760–7. doi:10.1002/gcc.20680.PubMedCrossRef Ganster C, Neesen J, Zehetmayer S, Jager U, Esterbauer H, Mannhalter C, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2009;48(9):760–7. doi:10.​1002/​gcc.​20680.PubMedCrossRef
8.
Zurück zum Zitat Li J (2011) Association of XRCC1 polymorphis with leukemia susceptibility in northwest Chinese population. Li J (2011) Association of XRCC1 polymorphis with leukemia susceptibility in northwest Chinese population.
9.
10.
Zurück zum Zitat Zhang Y, Wang Y, Wu J, Li LJ. XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2321–7. doi:10.1007/s13277-013-0779-y.CrossRef Zhang Y, Wang Y, Wu J, Li LJ. XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2321–7. doi:10.​1007/​s13277-013-0779-y.CrossRef
11.
Zurück zum Zitat Shen M, Purdue MP, Kricker A, Lan Q, Grulich AE, Vajdic CM, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia. Haematologica. 2007;92(9):1180–5.PubMedCrossRef Shen M, Purdue MP, Kricker A, Lan Q, Grulich AE, Vajdic CM, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia. Haematologica. 2007;92(9):1180–5.PubMedCrossRef
13.
Zurück zum Zitat Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res: GMR. 2009;8(4):1451–8. doi:10.4238/vol8-4gmr687.PubMedCrossRef Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res: GMR. 2009;8(4):1451–8. doi:10.​4238/​vol8-4gmr687.PubMedCrossRef
14.
Zurück zum Zitat Zhao W, Luo J, Cai X. Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2383–8. doi:10.1007/s13277-013-0787-y.CrossRef Zhao W, Luo J, Cai X. Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2383–8. doi:10.​1007/​s13277-013-0787-y.CrossRef
15.
Zurück zum Zitat Chen W, Zhao H, Li T, Yao H. HFE gene C282Y variant is associated with colorectal cancer in Caucasians: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2255–9. doi:10.1007/s13277-013-0766-3.CrossRef Chen W, Zhao H, Li T, Yao H. HFE gene C282Y variant is associated with colorectal cancer in Caucasians: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2255–9. doi:10.​1007/​s13277-013-0766-3.CrossRef
17.
Zurück zum Zitat Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatric Blood Cancer. 2007;48(1):16–20. doi:10.1002/pbc.20742.PubMedCrossRef Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatric Blood Cancer. 2007;48(1):16–20. doi:10.​1002/​pbc.​20742.PubMedCrossRef
18.
Zurück zum Zitat Ren LJ, Zhang QH, Shi JY, Zhang QL, Jiang XX, Hou SL, et al. Polymorphisms of DNA repair genes XRCC1 and susceptibility to non-Hodgkin lymphoma. Baixuebing He Linbaliu. 2009;18(4):197–200. Ren LJ, Zhang QH, Shi JY, Zhang QL, Jiang XX, Hou SL, et al. Polymorphisms of DNA repair genes XRCC1 and susceptibility to non-Hodgkin lymphoma. Baixuebing He Linbaliu. 2009;18(4):197–200.
19.
Zurück zum Zitat Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, Roos G, Ryder LP, Falk KI, Palmgren J, Kere J, Melbye M, Glimelius B, Adami HO (2006) Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15 (2):258–265. doi:10.1158/1055-9965.EPI-05-0583 Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, Roos G, Ryder LP, Falk KI, Palmgren J, Kere J, Melbye M, Glimelius B, Adami HO (2006) Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15 (2):258–265. doi:10.​1158/​1055-9965.​EPI-05-0583
20.
Zurück zum Zitat Zhu R, Wu Y, Lu FJ, Wang AH, Tang JY, Zhao JC, et al. Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: a case–control analysis. Eur J Oncol. 2008;13(3):187–92. Zhu R, Wu Y, Lu FJ, Wang AH, Tang JY, Zhao JC, et al. Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: a case–control analysis. Eur J Oncol. 2008;13(3):187–92.
Metadaten
Titel
The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies
verfasst von
Xiang Tong
Jiqiao Yang
Yuanling Peng
Jiani Shen
Tianyuan Xiong
Yonggang Zhang
Hong Fan
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1232-y

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.